The Priority Review

Tag

GC Biopharma Corp

1 story

  1. Clinical trials

    GC Biopharma registers Phase 2/3 trial of GC3114B in adults 65 years or older

    The study plans to enroll 1806 participants and is expected to begin in October 2026. It is a multicenter, randomized, double-blind, active-controlled trial that will evaluate the safety of GC3114B and assess whether its immune response is non-inferior to that of the active control.